Enanta Pharmaceuticals (9EP) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Zelicapavir | Respiratory Syncytial Virus (Rsv), Rsv Infection, Rsv | Phase II | Not Yet Recruiting | A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus | Mar 16, 2026 | ― |
| Rosuvastatin, Midazolam, Caffeine, Edp-323 | Drug Drug Interaction, Rsv Infection | Phase I | Completed | A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants | Apr 01, 2025 | ― |
| Carbamazepine, Itraconazole, Fluconazole, Quinidine, Edp-323 | Drug Drug Interaction (Ddi), Rsv Infection | Phase I | Completed | A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323. | Feb 21, 2025 | ― |
| Moxifloxacin, Zelicapavir | Rsv Infection, Qtc Interval | Phase I | Completed | A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults | Aug 27, 2024 | ― |
| Edp-323 Dose Regimen 1, Edp-323 Dose Regimen 2 | Rsv Infection | Phase II | Completed | A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model | Nov 27, 2023 | ― |
| Edp-938 | Rsv Infection | Phase II | Completed | A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. | Oct 03, 2022 | ― |
| Edp-938 | Respiratory Syncytial Virus (Rsv) | Phase II | Completed | A Study to Evaluate EDP 938 Regimens in Children With RSV | Mar 23, 2021 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Zelicapavir | Phase II | Respiratory Syncytial Virus (Rsv), Rsv Infection, Rsv | Not Yet Recruiting | A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus | Mar 16, 2026 | ― |
| Rosuvastatin, Midazolam, Caffeine, Edp-323 | Phase I | Drug Drug Interaction, Rsv Infection | Completed | A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants | Apr 01, 2025 | ― |
| Carbamazepine, Itraconazole, Fluconazole, Quinidine, Edp-323 | Phase I | Drug Drug Interaction (Ddi), Rsv Infection | Completed | A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323. | Feb 21, 2025 | ― |
| Moxifloxacin, Zelicapavir | Phase I | Rsv Infection, Qtc Interval | Completed | A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults | Aug 27, 2024 | ― |
| Edp-323 Dose Regimen 1, Edp-323 Dose Regimen 2 | Phase II | Rsv Infection | Completed | A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model | Nov 27, 2023 | ― |
| Edp-938 | Phase II | Rsv Infection | Completed | A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. | Oct 03, 2022 | ― |
| Edp-938 | Phase II | Respiratory Syncytial Virus (Rsv) | Completed | A Study to Evaluate EDP 938 Regimens in Children With RSV | Mar 23, 2021 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Enanta Pharmaceuticals (CH:9EP) have in its pipeline
Enanta Pharmaceuticals CH:9EP is currently developing the following drugs: Zelicapavir, Rosuvastatin, Midazolam, Caffeine, Edp-323, Carbamazepine, Itraconazole, Fluconazole, Quinidine, Edp-323, Moxifloxacin, Zelicapavir, Edp-323 Dose Regimen 1, Edp-323 Dose Regimen 2, Edp-938. These drug candidates are in various stages of clinical development as the company works toward FDA approval.